Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | MME | P08473 | 3/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19573703 | 1.00 | CTSK (0.50) | CTSKCTSSMMESYKATM | |
| SCHEMBL9974745 | 0.89 | MME (0.61) | CTSKCTSSMMEATMSCN9A | |
| SCHEMBL9974741 | 0.89 | MME (0.61) | CTSKCTSSMMEATMSCN9A | |
| SCHEMBL18597975 | 0.89 | MME (0.61) | CTSKCTSSMMEATMSCN9A | |
| SCHEMBL9963896 | 0.89 | MME (0.61) | CTSKCTSSMMEATMSCN9A | |
| SCHEMBL18995171 | 0.86 | CTSK (0.47) | CTSKCTSSSYKATMSCN9A | |
| SCHEMBL19605638 | 0.80 | CTSK (0.63) | CTSKCTSSMMEPPARAPPARG | |
| SCHEMBL22651626 | 0.80 | CTSK (0.63) | CTSKCTSSMMEPPARAPPARG | |
| SCHEMBL344068 | 0.80 | CTSK (0.63) | CTSKCTSSMMEPPARAPPARG | |
| SCHEMBL18576747 | 0.79 | MME (0.54) | CTSKCTSSMMEATMSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005740-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-06-26 | — | — | US | disclosed |
| US-9688692-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170022219-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022219-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CTSK 178/4885CTSS 117/4885MME 1/4885 |
| US-10005740-B2 | Neprilysin inhibitors | MME, REN, AGTR1 | CTSK 176/4885CTSS 91/4885MME 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.